Study reveals how different plant saponins alleviate ischemic stroke

https://www.news-medical.net/news/20261012/Study-reveals-how-different-plant-saponins-alleviate-ischemic-stroke.aspx Ischemic stroke accounts for approximately 85% of all strokes and remains a major cause of death and long-term disability. Current treatments can restore blood flow in eligible patients, but therapeutic options remain limited, particularly for protecting threatened brain tissue and supporting recovery. P. notoginseng and P. ginseng have long been used in traditional Chinese medicine and are commonly associated with "activating blood" and "replenishing qi," respectively. Modern studies have reported anti-inflammatory, antioxidant, and anti-apoptotic effects for their saponins. However, conventional bulk and single-cell analyses cannot fully show where drug-induced molecular changes occur within the spatially heterogeneous brain, leaving the regional differences between these treatments insufficiently understood.

Think raw milk is better for you? Pediatricians have a warning

https://www.news-medical.net/news/20261012/Think-raw-milk-is-better-for-you-Pediatricians-have-a-warning.aspx With hundreds of illnesses linked to raw milk outbreaks and emerging concerns over bird flu, pediatricians warn that unpasteurized dairy poses preventable health risks without delivering the nutritional benefits its supporters claim. A recent policy statement from the American Academy of Pediatrics (AAP), published in Pediatrics, concluded that raw milk offers no proven health advantages over pasteurized milk that outweigh its increased risk of foodborne illness.

Med Op-Ed: Supplements, Costs, and Value in Cancer Care Edited by Victoria Stern

https://www.medscape.com/viewarticle/med-op-ed-supplements-costs-and-value-cancer-care-2026a10011ox?ecd=WNL_trdalrt_pos1_ous_261012_etid8786199&uac=148436CN&impID=8786199 In this installment of Med Op-Ed: What should patients know about supplements during cancer treatment? How can oncologists approach conversations about the costs of care? And is cancer care being valued and reimbursed appropriately?

The latest edition of RARE Revolution Magazine has dropped—The RARE-linked edition is now LIVE!

https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=a879f992-d7b6-4577-a1e2-3ba26643b60c The community turning the tide for RARE and X-linked disorders The Autumn 2026 edition of RARE Revolution Magazine (Issue 037) has landed! This edition focuses on X-linked genetic disorders, a category encompassing over 500 conditions linked to variants on the X chromosome. The edition highlights a pivotal shift across the rare disease ecosystem—contrasting the challenges of diagnostic odysseys, insurance coverage battles and adult transition gaps with groundbreaking progress in targeted therapies, parent-led translational research and global community building. Above all, it celebrates the extraordinary strength and everyday joy found within rare disease families. Featuring: Great expectations: reframing life with Renpenning syndrome – An interview with rare parent and advocate Jessica Nunley on releasing preconceived expectations, navigating early intervention, and advocating for her son Gryffin. 60 years of fast-paced progress in Rett syndrome – Professor Dimitrios I. Zafeiriou reflects on six decades of evolution in Rett syndrome care, moving from basic symptom management to targeted treatments and gene therapy trials. The heart, soul, and glue of Wiskott-Aldrich syndrome – The story of how Mike Skrynecki and Dr Sumathi Iyengar co-founded the Wiskott-Aldrich Foundation, rescued an almost-abandoned gene therapy programme and reshaped global care standards. Living on a "cliff edge": fragile X and the fight for Austin’s future – Georgina Fane shares the realities of raising her 17-year-old son Austin and the looming systemic battle surrounding transition into adult care services. Plus so much more, including – Menkes disease, CASK, Barth syndrome, XLP1, XLA, Fabry disease, Aicardi syndrome and much more. You can view this publication from a desktop, laptop, mobile or tablet and it is packed with interactive links so you can enjoy the best possible experience when engaging with the content. And don't forget you can also view from our website at any time, along with lots of other great digital content. www.rarerevolutionmagazine.com https://rarerevolutionmagazine.com/

The Next Frontier in Metastatic CRPC: The EZH2 Pathway and Emerging Therapies Authors: Elena Castro, MD, PhD; Michael Schweizer, MD; Neal D. Shore, MD, FACS

https://www.medscape.org/viewarticle/next-frontier-metastatic-crpc-ezh2-pathway-and-emerging-2026a10009uq?page=1&src=mkmcmr_driv_stan_mscpedu_261009-OUS-HONC-next-frontier-metastatic-crpc-ezh2-pathway-and-emerging-2026a10009uq-cta&uac=148436CN

Pancreatic Cancer Therapy Rates Diverge Sharply in US, Dutch Data Megan Brooks

https://www.medscape.com/viewarticle/pancreatic-cancer-therapy-rates-diverge-sharply-us-dutch-2026a10011iq?ecd=WNL_trdalrt_pos1_ous_261009_etid8776881&uac=148436CN&impID=8776881 Two large real-world studies of patients with metastatic pancreatic cancer — one from Netherlands and one from the US — paint strikingly different pictures of systemic therapy use. A nationwide Dutch study reported that nearly three quarters of patients with metastatic pancreatic cancer did not receive systemic therapy, whereas a contemporary US cohort study found that only one third did not receive treatment.

Rethinking lived experience The Lancet (++... +)

Rethinking lived experience The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02038-6/fulltext?dgcid=raven_jbs_etoc_email The theme of this year's World Mental Health Day, held on Oct 10, is Lived experiences heard: real voices, real change. On its website, WHO states that the voices of people with lived experience should “shape the policies, services and decisions that affect their lives”. While these are laudable aims, they also serve to highlight the complex challenges involved in lived experience engagement and co-production, both within the field of mental health and beyond. Oct 10, 2026 Volume 408Number 10563p1397-1524 https://www.thelancet.com/journals/lancet/issue/vol408no10563/PIIS0140-6736(26)X2038-4 Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial Virginia Bellido, PhDa Send email to virginiabellido@gmail.com ∙ Carel W le Roux, PhDb,c ∙ Elif I Ekinci, PhDd,e ∙ Petter Bjornstad, MDf ∙ Juan P Frias, MDg ∙ Kathryn Giblin, MDh ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01861-1/abstract?dgcid=raven_jbs_etoc_feature_lancet